Political Punching Bags

by William Smead, Smead Capital Management

The United States has one of the most successful biotech/pharmaceutical industries and arguably the premier banking institutions in the world. During the current presidential race, populist politicians on both sides of the aisle have gained a great deal of popularity by turning these two industries into political punching bags.

Printer-friendly version


POLL


To date, what impact has CRM2 had on your business?

View Results

Loading ... Loading ...

Consider the characteristics of a punching bag: its composition, strength and durability.

A punching bag is built with a cylindrical shape and has a very strong exterior cover. It is composed of materials which absorb the blows of a boxer or a martial arts specialist. The outer covering stretches while the interior materials give way to protect the puncher’s fists, arms, feet and legs. Despite the abuse a punching bag takes, it returns to its normal form after numerous daily assaults.

At Smead Capital Management, our eight criteria for stock selection look for a certain composition, strength and durability in a company. To qualify for our portfolio, a company must meet an economic need and have significant barriers to entry to ward off potential competitors. The company has to have a history of high profitability, consistent free cash flow generation and be available at a bargain price compared to the last five to ten years of trading. We also prefer companies to have a strong balance sheet, history demonstrated shareholder friendliness and have significant insider ownership, preferably with recent insider purchases.

These eight criteria allow the companies in our portfolio to take punches over the years from potential competitors and government regulators ― and take political kicks in the face from populist candidates. They are strong and durable just like a punching bag.

Bernie Sanders, Hillary Clinton and Donald Trump have been racing to see who could give away the most healthcare freebies. Even though prescription pharmaceuticals are only 10% of the cost of healthcare in the U.S., these politicians would like voters to think that political pressure on ‘Big Pharma/Biotech’ would solve all our healthcare expense problems.1 It reminds me of Pedro running for class president in the movie, Napolean Dynamite. In the movie, Pedro told his fellow students, “Vote for me and all your dreams will come true.”

Investors act like this is the first time these companies have been punched. From 2003 to 2011, the regulatory, political and legal environment for Amgen, Merck, Pfizer and others was miserable. The Food and Drug Administration was tight as a drum, the populists were out in force and Vioxx lawsuits were large and fresh in investors’ minds. If these companies weren’t as strong as a punching bag, their mouths would have been bloody and their teeth would have fallen out. Fortunately, they have seen their moats get bigger and their future get brighter as improving science has led them to breakthrough medicines needed by an ever-growing population.

Pages ( 1 of 2 ): 1 2Next »

About the author

William Smead

Chief Executive Officer/Chief Investment Officer

Whitman College, B.A. Economics 1980

William is the founder of Smead Capital Management, where he oversees all activities of the firm. As Chief Investment Officer, he is the final decision-maker for all investment and portfolio decisions as well as reviewing the implementation of those decisions in the firm’s separate accounts and mutual funds.

William began his career in the investment business with Drexel Burnham Lambert in 1980. He left Drexel Burham Lambert in 1989 as First Vice President/Assistant Manager and joined Oppenheimer & Co., where he stayed until joining Smith Barney in 1990. William remained at Smith Barney until September 2001 when he joined Wachovia Securities becoming the Managing Director/Portfolio Manager of Smead Investment Group of Wachovia Securities. In 2007, William left Wachovia Securities to found Smead Capital Management.

Related Posts

You may also like

Mid-Year Outlook: Tug of War

Tug of War by William Smead, Smead Capital